INTERVENÇÕES LIDERADAS POR FARMACÊUTICOS PARA A PROFILAXIA RACIONAL DA LESÃO DE MUCOSA RELACIONADA AO ESTRESSE EM UTIS

UMA REVISÃO INTEGRATIVA

Visualizações: 303

Autores

DOI:

https://doi.org/10.56579/rei.v7i4.1689

Palavras-chave:

Terapia Intensiva, Deprescrição, Segurança do Paciente, Farmácia Clínica, Lesão da Mucosa Relacionada ao Estresse

Resumo

As intervenções farmacêuticas melhoram os desfechos clínicos na profilaxia de lesão da mucosa relacionada ao estresse (LMRE) em unidades de terapia intensiva (UTIs) e reduzem os custos hospitalares. Esta revisão identifica estratégias de farmacêuticos para reduzir o uso inadequado de inibidores da bomba de prótons (IBPs) na profilaxia de lesão aguda da mucosa gástrica (LAMG) em pacientes de UTI.  Foi realizada uma revisão integrativa em bases de dados como BVS, LILACS, PubMed (MEDLINE), SciELO, Cochrane Library e Google Scholar, com foco em estudos dos últimos 5 anos (até novembro de 2022). Utilizou-se uma abordagem descritiva para analisar as intervenções farmacêuticas e seus resultados. Dos 204 registros identificados, 9 artigos atenderam aos critérios de inclusão. Intervenções como diretrizes e protocolos aumentaram a eficácia clínica da profilaxia de LMRE em UTIs, garantindo prescrições adequadas e adesão às diretrizes. Essas estratégias também reduziram significativamente os custos mensais e anuais. A participação de farmacêuticos clínicos no desenvolvimento de diretrizes de profilaxia de LMRE e nas discussões multidisciplinares mostrou-se a estratégia mais eficaz para melhorar os desfechos. Contudo, são necessários mais estudos para avaliar a relação custo-efetividade dessas intervenções. 

Downloads

Não há dados estatísticos.

Biografia do Autor

Luana Caroline Radun, Universidade Federal de Santa Catarina

Aluna do Programa de Mestrado em Assistência Farmacêutica da Universidade Federal de Santa Catarina e Centro Hospitalar Unimed, Joinville, Santa Catarina, Brasil.

Filipe Carvalho Matheus, Universidade Federal de Santa Catarina

Docente do Programa de Pós-Graduação em Assistência Farmacêutica da Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brasil.

Referências

AMIR, M.; KHAN, F. Role of clinical pharmacist in implementation of stress ulcer prophylaxis protocol: a single site retrospective study. RADS Journal of Pharmacy and Pharmaceutical Sciences, [S. l.], v. 9, n. 4, p. 225-230, 2021.

ANSTEY, M. H. et al. Clinical and economic benefits of de-escalating stress ulcer prophylaxis therapy in the intensive care unit: a quality improvement study. Anaesthesia and Intensive Care, [S. l.], v. 47, n. 6, p. 503-509, nov. 2019. DOI: 10.1177/0310057X19860972. DOI: https://doi.org/10.1177/0310057X19860972

ASHP – AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS. ASHP therapeutic guidelines on stress ulcer prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. American Journal of Health-System Pharmacy, [S. l.], v. 56, n. 4, p. 347-379, 15 fev. 1999. DOI: 10.1093/ajhp/56.4.347. DOI: https://doi.org/10.1093/ajhp/56.4.347

BAZAN, N. S.; FARID, S. F.; BAINES, D. L. Impact of clinical pharmacists on adherence to stress ulcer prophylaxis protocol in critically ill Egyptian patients: a comparative study. Drugs and Therapy Perspectives, [S. l.], v. 37, p. 35–43, 2021. DOI: https://doi.org/10.1007/s40267-020-00786-y. DOI: https://doi.org/10.1007/s40267-020-00786-y

BARLETTA, J. F. et al. Stress ulcer prophylaxis. Critical Care Medicine, [S. l.], v. 44, n. 7, p. 1395-1405, jul. 2016. DOI: 10.1097/CCM.0000000000001872. DOI: https://doi.org/10.1097/CCM.0000000000001872

BEN-MENACHEM, T. et al. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit: a randomized, controlled, single-blind study. Annals of Internal Medicine, [S. l.], v. 121, n. 8, p. 568-575, 15 out. 1994. DOI: 10.7326/0004-819-121-8-199410150-00003. DOI: https://doi.org/10.7326/0003-4819-121-8-199410150-00003

BROWN, D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promotion Practice, [S. l.], v. 21, n. 4, p. 496-498, jul. 2020. DOI: 10.1177/1524839919893361. DOI: https://doi.org/10.1177/1524839919893361

CEEINTER. Centro de Estudos Interdisciplinares Página Inicial. [S.l.]. Florianópolis, c2023. Disponível em: https://portal.ceeinter.com.br/. Acesso em: 10 de set. 2023.

COOK, D. J. et al. Risk factors for gastrointestinal bleeding in critically ill patients. The New England Journal of Medicine, [S. l.], v. 330, n. 6, p. 377-381, 10 fev. 1994. DOI: 10.1056/NEJM199402103300601. DOI: https://doi.org/10.1056/NEJM199402103300601

COOK, D. J. et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Critical Care, [S. l.], v. 5, n. 6, p. 368-375, dez. 2001. DOI: 10.1186/cc1071. DOI: https://doi.org/10.1186/cc1071

FRANCHITTI, M. et al. Adequacy of stress ulcer prophylaxis prescription in the intensive care unit: an observational study. Swiss Medical Weekly, [S. l.], v. 150, p. w20322, 24 ago. 2020. DOI: 10.4414/smw.2020.20322. DOI: https://doi.org/10.4414/smw.2020.20322

GUILLAMONDEGUI, O. D. et al. Practice management guidelines for stress ulcer prophylaxis. Chicago, IL: Eastern Association for the Surgery of Trauma, 2008. 24 p.

GRUBE, R. R.; MAY, D. B. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. American Journal of Health-System Pharmacy, [S. l.], v. 64, n. 13, p. 1396-1400, 1 jul. 2007. DOI: 10.2146/ajhp060393. DOI: https://doi.org/10.2146/ajhp060393

HAASE, N. et al. Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial. Intensive Care Medicine, [S. l.], v. 39, n. 12, p. 2126-2134, dez. 2013. DOI: 10.1007/s00134-013-3111-9. DOI: https://doi.org/10.1007/s00134-013-3111-9

HATCH, J. B.; SCHULZ, L.; FISH, J. T. Stress ulcer prophylaxis: reducing non-indicated prescribing after hospital discharge. Annals of Pharmacotherapy, [S. l.], v. 44, n. 10, p. 1565-1571, out. 2010. DOI: 10.1345/aph.1P167. DOI: https://doi.org/10.1345/aph.1P167

HONG, Y. et al. Continuous improvement on the rationality of prophylactic injectable PPIs usage by a clinical pharmacist-led guidance team at a Chinese tertiary teaching hospital. Journal of International Medical Research, [S. l.], v. 48, n. 10, p. 1-10, out. 2020. DOI: 10.1177/0300060520954729. DOI: https://doi.org/10.1177/0300060520954729

KRAG, M. et al. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Medicine, [S. l.], v. 41, n. 5, p. 833-845, maio 2015. DOI: 10.1007/s00134-015-3725-1. DOI: https://doi.org/10.1007/s00134-015-3725-1

LUO, H. et al. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists' effect on prescribing practice at a tertiary hospital. BMC Health Services Research, [S. l.], v. 18, n. 1, p. 537, 11 jul. 2018. DOI: 10.1186/s12913-018-3358-5. DOI: https://doi.org/10.1186/s12913-018-3358-5

MADSEN, K. R. et al. Guideline for stress ulcer prophylaxis in the intensive care unit. Danish Medical Journal, [S. l.], v. 61, n. 3, p. C4811, mar. 2014. PMID: 24814922. Disponível em: https://ugeskriftet.dk/dmj/guideline-stress-ulcer-prophylaxis-intensive-care-unit. Acesso em: 17 jul. 2025.

MAHMOUDI, L.; MOHAMMADI, R.; NIKNAM, R. Economic impact of pharmacist interventions on correction of stress-related mucosal damage prophylaxis practice. ClinicoEconomics and Outcomes Research, [S. l.], v. 11, p. 111-116, 25 jan. 2019. DOI: 10.2147/CEOR.S191304. DOI: https://doi.org/10.2147/CEOR.S191304

MASOOD, U. et al. A successful pharmacist-based quality initiative to reduce inappropriate stress ulcer prophylaxis use in an academic medical intensive care unit. Inquiry, [S. l.], v. 55, p. 1-6, jan./dez. 2018. DOI: 10.1177/0046958018759116. DOI: https://doi.org/10.1177/0046958018759116

MOUSAVI, M. et al. Impact of clinical pharmacy services on stress ulcer prophylaxis prescribing and related cost in patients with renal insufficiency. International Journal of Pharmacy Practice, [S. l.], v. 21, n. 4, p. 269, ago. 2013. DOI: 10.1111/ijpp.12005. DOI: https://doi.org/10.1111/ijpp.12005

MUÑOZ-PICHUANTE, D.; VILLA-ZAPATA, L. Benefit of incorporating clinical pharmacists in an adult intensive care unit: a cost-saving study. Journal of Clinical Pharmacy and Therapeutics, [S. l.], v. 45, n. 5, p. 1127-1133, out. 2020. DOI: 10.1111/jcpt.13195. DOI: https://doi.org/10.1111/jcpt.13195

ORLANDO REGIONAL MEDICAL CENTER. Stress ulcer prophylaxis. 2011. Disponível em: http://www.surgicalcriticalcare.net/Guidelines/stress%20ulcer%20prophylaxis%202011.pdf. Acesso em: 17 jul. 2025.

PATI, D.; LORUSSO, L. N. How to write a systematic review of the literature. HERD: Health Environments Research & Design Journal, [S. l.], v. 11, n. 1, p. 15-30, jan. 2018. DOI: 10.1177/1937586717747384. DOI: https://doi.org/10.1177/1937586717747384

PHAM, C. Q. et al. Acid suppressive therapy use on an inpatient internal medicine service. Annals of Pharmacotherapy, [S. l.], v. 40, n. 7-8, p. 1261-1266, jul./ago. 2006. DOI: 10.1345/aph.1G703. DOI: https://doi.org/10.1345/aph.1G703

RHODES, A. et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Medicine, [S. l.], v. 43, n. 3, p. 304-377, mar. 2017. DOI: 10.1007/s00134-017-4683-6. DOI: https://doi.org/10.1007/s00134-017-4683-6

SAVARINO, V. et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Review of Clinical Pharmacology, [S. l.], v. 11, n. 11, p. 1123-1134, nov. 2018. DOI: 10.1080/17512433.2018.1531703. DOI: https://doi.org/10.1080/17512433.2018.1531703

SCHOENFELD, A. J.; GRADY, D. Adverse effects associated with proton pump inhibitors. JAMA Internal Medicine, [S. l.], v. 176, n. 2, p. 172-174, fev. 2016. DOI: 10.1001/jamainternmed.2015.7927. DOI: https://doi.org/10.1001/jamainternmed.2015.7927

VANDERBILT UNIVERSITY MEDICAL CENTER. Gastrointestinal stress ulcer prophylaxis guideline. 2005. Disponível em: http://traumaburn.com/Protocols/StressUlcerProphylaxisVisio.pdf. Acesso em: 17 jul. 2025.

WELLS, G. A. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. [S. l.], [s. n.], [20--]. Disponível em: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Acesso em: 30 ago. 2023.

YAILIAN, A. L. et al. Characteristics of pharmacists' interventions related to proton-pump inhibitors in French hospitals: an observational study. International Journal of Clinical Practice, [S. l.], v. 2022, p. 9619699, 28 jun. 2022. DOI: 10.1155/2022/9619699. DOI: https://doi.org/10.1155/2022/9619699

YE, Z. et al. Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. BMJ, [S. l.], v. 368, p. l6722, 6 jan. 2020. DOI: 10.1136/bmj.l6722. DOI: https://doi.org/10.1136/bmj.l6722

ZANDSTRA, D. F.; STOUTENBEEK, C. P. The virtual absence of stress-ulceration related bleeding in ICU patients receiving prolonged mechanical ventilation without any prophylaxis: a prospective cohort study. Intensive Care Medicine, [S. l.], v. 20, n. 5, p. 335-340, maio 1994. DOI: 10.1007/BF01720905. DOI: https://doi.org/10.1007/BF01720905

Downloads

Publicado

2025-07-23

Como Citar

Radun, L. C., & Matheus, F. C. (2025). INTERVENÇÕES LIDERADAS POR FARMACÊUTICOS PARA A PROFILAXIA RACIONAL DA LESÃO DE MUCOSA RELACIONADA AO ESTRESSE EM UTIS: UMA REVISÃO INTEGRATIVA. REVISTA DE ESTUDOS INTERDISCIPLINARES, 7(4), 01–16. https://doi.org/10.56579/rei.v7i4.1689

Métricas